Showing results (1831-1840 of 1,881) with videos related to

Sort By:
Pageof 189
Immunotherapy|September 18, 2023
Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphomaIrene Medina, Cecilia Carpio, Isabel Ruiz-Camps, et al.
Immunotherapy|September 13, 2024
The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLCYiran Rong, Sujith Ramachandran, Kaustuv Bhattacharya, et al.
Immunotherapy|September 12, 2024
Profiling of autoantibodies in the sera of glioblastoma patientsJohannes Low Jun Wei, Ammar Akram Kamarudin, Bee Hong Soon, et al.
Immunotherapy|September 12, 2024
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumorsBen Tran, Mark Voskoboynik, Johanna Bendell, et al.
Immunotherapy|October 8, 2024
Allogeneic CAR-T cells for cancer immunotherapyXinfeng Chen, Yaoxin Gao, Yi Zhang
Immunotherapy|October 17, 2024
Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapyAna Maria Meireles, Gloria Iacoboni, Leonardo Maia Moço, et al.
Immunotherapy|May 31, 2023
Neoadjuvant immunotherapy plus chemotherapy and adjuvant targeted therapy in ALK-positive non-small-cell lung cancerQi Song, Jie Li, Qi Xiong, et al.
Immunotherapy|May 31, 2023
Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summaryKristian Reich, Jacob P Thyssen, Andrew Blauvelt, et al.
Immunotherapy|November 28, 2024
Economics of first-line treatment with tislelizumab in patients with nonsquamous non-small cell lung cancerLin Wang, Ting Liu, Xihan Lin, et al.
Immunotherapy|December 2, 2024
Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscapeAlexander Röth, Austin G Kulasekararaj, Phillip Scheinberg, et al.
Pageof 189